1
Arterburn Linda Mary, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Van, Elswyk Mary: Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same. Martek Biosciences Corporation, Arterburn Linda Mary, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Van, Elswyk Mary, SEBOR Angela Dallas, May 26, 2006: WO/2006/055965 (16 worldwide citation)

Disclosed are novel oxylipins, referred to herein as docosanoids, that are derived from C22 polyunsaturated fatty acids, and method of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6) (DPAn-6), docosapentaenoic acid (C22:5n-3) (DPAn-3), and docosatetraen ...


2
Arterburn Linda, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Vinjamoori Dutt, Van, Elswyk Mary: Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same. Martek Biosciences Corporation, Arterburn Linda, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Vinjamoori Dutt, Van, Elswyk Mary, CONNELL Gary J, August 28, 2008: WO/2008/103753 (12 worldwide citation)

Disclosed are novel oxylipins, referred to herein as docosanoids and eicosanoids, that are derived from C22 polyunsaturated fatty acids and from C20 polyunsaturated fatty acids, respectively, and methods of making and using such oxylipins. Also disclosed is the use of docosapentaenoic acid (C22:5n-6 ...


3
Arterburn Linda, Benisek Diane, Hoffman James, Oken Harry A, Van, Elswyk Mary: Docohexaenoic acid for improved glycemic control. Martek Biosciences Corporation, Arterburn Linda, Benisek Diane, Hoffman James, Oken Harry A, Van, Elswyk Mary, POSORSKE Laurence H, April 8, 2004: WO/2004/028469 (5 worldwide citation)

This invention is directed to methods of treating patients with metabolic syndrome, prediabetes and/or Type 11 diabetes mellitus by administering docosahexaenoic acid (DHA) alone or in combination with diabetes-related medications.


4
Arterburn Linda M, Hoffman James P, Oken Harry A, Van, Elswyk Mary: Prophylactic docosahexaenoic acid therapy for patients with subclinical inflammation. Martek Biosciences Corporation, Arterburn Linda M, Hoffman James P, Oken Harry A, Van, Elswyk Mary, POSORSKE Laurence H, April 8, 2004: WO/2004/028470 (2 worldwide citation)

This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The meth ...


5
Arterburn Linda Mary, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Vinjamoori Dutt: Oxylipins from stearidonic acid and &ggr;-linolenic acid and methods of making and using the same. Martek Biosciences Corporation, Arterburn Linda Mary, Barclay William, Dangi Bindi, Flatt James, Lee Jung, Vinjamoori Dutt, SEBOR Angela Dallas, August 9, 2007: WO/2007/090162 (1 worldwide citation)

Disclosed are novel oxylipins that are derived from &ggr;-linolenic acid (GLA; 18:3n-6) and stearidonic acid (STA or SDA; 18:4n-3), and methods of making and using such oxylipins. Also disclosed is the use of such oxylipins in therapeutic and nutritional or cosmetic applications, and particularly as ...


6
Arterburn Linda, Barclay William, Flatt James, Van, Elswyk Mary, Zeller Samuel G: Use of dpa(n-6) oils in infant formula. Martek Biosciences Corporation, Arterburn Linda, Barclay William, Flatt James, Van, Elswyk Mary, Zeller Samuel G, YOERG Darla G, March 6, 2008: WO/2008/027991

Infant formula compositions containing docosapentaenoic acid n-6 ('DPA(n-6)') and other polyunsaturated fatty acids and methods for their preparation and use are provided.